Chardan initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $50 price target citing the potential of its QTORIN topical rapamycin gel as an “attractive” treatment in mTOR-driven genetic skin diseases plus the potential for platform upside on analogous topical drug products. Palvella is currently advancing QTORIN through late-stage trials in two vascular indications, microcystic lymphatic malformations and cutaneous venous malformations, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $53 from $39 at Canaccord
- Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
- High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
- Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
- Palvella Therapeutics Reports 2024 Financial Results and Updates